Additional payment of development milestone to achieve.

No definition available.

Name:	idya_AdditionalPaymentOfDevelopmentMilestoneToAchieve
Namespace Prefix:	idya_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Additional payments for achievement of specific development and regulatory approval events.

+ References

No definition available.

+ Details

Name:	idya_AdditionalPaymentsForAchievementOfSpecificDevelopmentAndRegulatoryApprovalEvent
Namespace Prefix:	idya_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Certain commercial sales milestones payment to be paid.

+ References

No definition available.

+ Details

Name:	idya_CertainCommercialSalesMilestonesPaymentToBePaid
Namespace Prefix:	idya_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Commercial milestone payment to be received.

+ References

No definition available.

+ Details

Name:	idya_CommercialMilestonePaymentToBeReceived
Namespace Prefix:	idya_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Development and regulatory milestone payment to be paid.

+ References

No definition available.

+ Details

Name:	idya_DevelopmentAndRegulatoryMilestonePaymentToBePaid
Namespace Prefix:	idya_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Development and regulatory milestone payment to be received.

+ References

No definition available.

+ Details

Name:	idya_DevelopmentAndRegulatoryMilestonePaymentToBeReceived
Namespace Prefix:	idya_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Development costs sharing percentage.

+ References

No definition available.

+ Details

Name:	idya_DevelopmentCostsSharingPercentage
Namespace Prefix:	idya_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Development milestone payment to be received.

+ References

No definition available.

+ Details

Name:	idya_DevelopmentMilestonePaymentToBeReceived
Namespace Prefix:	idya_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Development milestone payments of phase three relating to first and second tumor histologies.

+ References

No definition available.

+ Details

Name:	idya_DevelopmentMilestonePaymentsOfPhaseThreeRelatingToFirstAndSecondTumorHistologies
Namespace Prefix:	idya_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Development milestone payments of phase two relating to first and second tumor histologies.

+ References

No definition available.

+ Details

Name:	idya_DevelopmentMilestonePaymentsOfPhaseTwoRelatingToFirstAndSecondTumorHistologies
Namespace Prefix:	idya_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Early clinical development milestone payment potential to receive.

+ References

No definition available.

+ Details

Name:	idya_EarlyClinicalDevelopmentMilestonePaymentPotentialToReceive
Namespace Prefix:	idya_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Milestone payment received clinical evaluation

+ References

No definition available.

+ Details

Name:	idya_MilestonePaymentReceivedClinicalEvaluation
Namespace Prefix:	idya_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Milestone payment received for achievement of initial preclinical development milestone.

+ References

No definition available.

+ Details

Name:	idya_MilestonePaymentReceivedForAchievementOfInitialPreclinicalDevelopmentMilestone
Namespace Prefix:	idya_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Milestone payments relating to first and second tumor histologies.

+ References

No definition available.

+ Details

Name:	idya_MilestonePaymentsRelatingToFirstAndSecondTumorHistologies
Namespace Prefix:	idya_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Number of days of notice period for terminating collaboration agreement.

+ References

No definition available.

+ Details

Name:	idya_NumberOfDaysOfNoticePeriodForTerminatingCollaborationAgreement
Namespace Prefix:	idya_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Pay for external third-party cost percentage.

+ References

No definition available.

+ Details

Name:	idya_PayForExternalThirdPartyCostPercentage
Namespace Prefix:	idya_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Payment of one-time option exercise fee.

+ References

No definition available.

+ Details

Name:	idya_PaymentOfOneTimeOptionExerciseFee
Namespace Prefix:	idya_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Payments for achievement of specific development and regulatory approval events.

+ References

No definition available.

+ Details

Name:	idya_PaymentsForAchievementOfSpecificDevelopmentAndRegulatoryApprovalEvents
Namespace Prefix:	idya_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Percentage of profit share.

+ References

No definition available.

+ Details

Name:	idya_PercentageOfProfitShare
Namespace Prefix:	idya_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Preclinical development milestone payment potential to receive.

+ References

No definition available.

+ Details

Name:	idya_PreclinicalDevelopmentMilestonePaymentPotentialToReceive
Namespace Prefix:	idya_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Upfront payment.

+ References

No definition available.

+ Details

Name:	idya_UpfrontPayment
Namespace Prefix:	idya_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479402/808-10-50-1

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

+ Details

Name:	us-gaap_PreferredStockSharesIssued
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Details

Name:	us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=idya_NovartisInternationalPharmaceuticalsLimitedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementClassOfStockAxis=idya_SeriesBRedeemableConvertiblePreferredStockMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=idya_CancerResearchTechnologyAndTheUniversityOfManchesterMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=idya_AmgenClinicalTrialCollaborationAndSupplyAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=idya_GlaxoSmithKlineCollaborationAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=idya_GlaxoSmithKlineMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=idya_PolymeraseThetaProgramMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=idya_WernerHelicaseProgramMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Significant Agreements - Additional Information (Details) $ in Millions		1 Months Ended
	Jul. 31, 2020 USD ($)	Oct. 31, 2023 USD ($)	Apr. 30, 2023 GBP (£)	Aug. 31, 2022 USD ($)	Jul. 31, 2022	Jan. 31, 2022 GBP (£)	Jun. 30, 2020 USD ($)	Sep. 30, 2018 USD ($) shares	Jun. 30, 2024 USD ($) shares	Jun. 30, 2024 GBP (£) shares	Dec. 31, 2023 shares	Aug. 31, 2023 USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Preferred stock, shares issued \| shares									0	0	0
License Agreement \| Novartis International Pharmaceuticals Limited
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront payment								$ 2.5
License Agreement \| Novartis International Pharmaceuticals Limited \| Series B Redeemable Convertible Preferred Stock
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Preferred stock, shares issued \| shares								263,615
License Agreement \| Cancer Research Technology and the University of Manchester
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Payment of one-time option exercise fee \| £						£ 250,000
Payments for achievement of specific development and regulatory approval events \| £						£ 19,500,000
Milestone payments relating to first and second tumor histologies \| £			£ 750,000
License Agreement \| Amgen Clinical Trial Collaboration and Supply Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Pay for external third-party cost percentage					50.00%
Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Early clinical development milestone payment potential to receive		$ 17.0
Maximum \| License Agreement \| Novartis International Pharmaceuticals Limited
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Certain clinical and regulatory development milestones, agreed to make a payment								$ 9.0
Certain commercial sales milestones, agreed to make a payment								$ 20.0
Maximum \| License Agreement \| Cancer Research Technology and the University of Manchester
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Additional payments for achievement of specific development and regulatory approval events \| £										£ 18,750,000
Milestone payments of phase two relating to first and second tumor histologies \| £										1,500,000
Milestone payments of phase two relating to first and second tumor histologies \| £										£ 2.25
GSK Collaboration Agreement \| GSK
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Development and regulatory milestone payment eligible to receive									$ 13.0
GSK Collaboration Agreement \| GSK \| License Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront payment	$ 100.0
Number of days of notice period for terminating agreement							90 days
Pol Theta Program
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone payment received for achievement of initial preclinical development milestone				$ 3.0
Milestone payment received clinical evaluation												$ 7.0
Additional payment of development milestone to achieve									10.0
Pol Theta Program \| Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Development and regulatory milestone payment eligible to receive							$ 485.0
Commercial milestone payment eligible to receive							$ 475.0
Development milestone payment eligible to receive									$ 465.0
WRN Program
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Development costs sharing percentage							20.00%
Milestone payment received for achievement of initial preclinical development milestone		3.0
Milestone payment received clinical evaluation		3.0
Percentage of profit share							50.00%
WRN Program \| Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Commercial milestone payment eligible to receive							$ 475.0
Preclinical development milestone payment potential to receive		7.0
Development milestone payment eligible to receive		$ 465.0					$ 485.0
WRN Program \| GSK
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Development costs sharing percentage							80.00%